Spada A, Lania A, Ballarè E
Institute of Endocrine Sciences, University of Milan, Ospedale Maggiore IRCCS, Milano, Italy.
Mol Cell Endocrinol. 1998 Jul 25;142(1-2):1-14. doi: 10.1016/s0303-7207(98)00116-6.
It has been demonstrated that the majority of secreting and nonsecreting adenomas is monoclonal in origin suggesting that these neoplasia arise from the replication of a single mutated cell, in which growth advantage results from either activation of protooncogenes or inactivation of antioncogenes. Although a large number of genes has been screened for mutations, only few genetic abnormalities have been found in pituitary tumors such as allelic deletion of chromosome 11q13 where the MEN-1 gene has been localised, and mutations in the gene encoding the alpha subunit of the stimulatory Gs and Gi2 protein. These mutations constitutively activate the alpha subunit of the Gs and Gi2 protein by inhibiting their intrinsic GTPase activity. Both Gs alpha and Gi2alpha can be considered products of protooncogenes (gsp and gip2, respectively) since gain of function mutations that activate mitogenic signals have been recognized in human tumors. Gsp oncogene is found in 30-40% of GH-secreting adenomas, in a low percentage of nonfunctioning and ACTH-secreting pituitary adenomas, in toxic thyroid adenomas and differentiated thyroid carcinomas. The same mutations, occurred early in embriogenesis, have been also identified in tissues from patients affected with the McCune Albright syndrome. These mutations result in an increased cAMP production and in the subsequent overactivation of specific pathways involved in both cell growth and specific programmes of cell differentiation. By consequence, the endocrine tumors expressing gsp oncogene retain differentiated functions. The gip2 oncogene has been identified in about 10% of nonfunctioning pituitary adenomas, in tumors of the ovary and the adrenal cortex. However, it remains to be established whether Gi proteins activate mitogenic signals in pituitary cells. Since Gi proteins are involved in mediating the effect of inhibitory neurohormones on intracellular effectors, it has been proposed that in pituitary tumors the low expression of these proteins, particularly Gi1-3alpha, may contribute to uncontrolled pituitary cells growth by preventing the transduction of inhibitory signals. While by in vitro mutagenesis it has been demonstrated that activated mutant of Gq alpha, G12alpha, G13alpha and Gz alpha are fully oncogenic, it remains to be proved whether or not these abnormalities might naturally occur in human tumors and, in particular, in pituitary adenomas.
已证实,大多数分泌性和非分泌性腺瘤起源于单克隆,这表明这些肿瘤是由单个突变细胞的复制产生的,其中生长优势源于原癌基因的激活或抗癌基因的失活。尽管已经筛选了大量基因的突变,但在垂体肿瘤中仅发现了少数基因异常,如11q13染色体的等位基因缺失(MEN-1基因定位于此),以及编码刺激性Gs和Gi2蛋白α亚基的基因突变。这些突变通过抑制其内在的GTP酶活性,组成性地激活Gs和Gi2蛋白的α亚基。Gsα和Gi2α都可被视为原癌基因的产物(分别为gsp和gip2),因为在人类肿瘤中已识别出激活有丝分裂信号的功能获得性突变。gsp原癌基因在30%-40%的生长激素分泌性腺瘤中发现,在低比例的无功能和促肾上腺皮质激素分泌性垂体腺瘤、毒性甲状腺腺瘤和分化型甲状腺癌中也有发现。同样在胚胎发育早期发生的这些突变,也在患有McCune Albright综合征患者的组织中被鉴定出来。这些突变导致cAMP产生增加,并随后过度激活参与细胞生长和细胞分化特定程序的特定途径。因此,表达gsp原癌基因的内分泌肿瘤保留了分化功能。gip2原癌基因已在约10%的无功能垂体腺瘤、卵巢和肾上腺皮质肿瘤中被鉴定出来。然而,Gi蛋白是否在垂体细胞中激活有丝分裂信号仍有待确定。由于Gi蛋白参与介导抑制性神经激素对细胞内效应器的作用,有人提出在垂体肿瘤中,这些蛋白,特别是Gi1-3α的低表达,可能通过阻止抑制性信号的转导而导致垂体细胞生长失控。虽然通过体外诱变已证明Gqα、G12α、G13α和Gzα的激活突变体具有完全致癌性,但这些异常是否会在人类肿瘤中自然发生,特别是在垂体腺瘤中,仍有待证实。